Navigation Links
Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey

MALVERN, Pa., June 15, 2007 /PRNewswire/ -- Solstice Neurosciences, Inc. today reported important results from a multicenter, forced dose escalation study of Botulinum Toxin Type B Injectable Solution (Myobloc(R)) recently presented at the 11th International Congress of The Movement Disorders Society in Istanbul, Turkey.

This was the first multicenter study to confirm patient safety and efficacy of escalating treatment doses of 10,000 Units, 12,500 Units, and 15,000 Units of Botulinum Toxin Type B in patients with cervical dystonia (CD).

The study results were presented by Eric J. Pappert, MD, who is assistant professor of neurology and director of the Parkinson's Disease and Movement Disorders Program at the University of Texas Health Science Center in San Antonio, Texas. Dr. Pappert also serves as Vice President, Medical & Scientific Affairs of Solstice Neurosciences.

"The recommended initial dose of Type B Toxin for patients with a prior history of tolerating botulinum toxin injections is 2,500 to 5,000 Units, with subsequent dosing to be optimized according to individual patient response. Pivotal clinical trials have used doses of 5,000 and 10,000 Units," said Dr. Pappert. "So, these data provide important insights for understanding how patients respond to higher doses. The results will also help guide the design of future studies."

    Highlights from the open-label study included the following:


    -- 145 Subjects (95% Caucasian, 65% Female, Mean Age=53.1 years)

    -- Previous experience with neurotoxins

       -- Resistant to Type A (n=32; 22%)

       -- Responsive to Type A (n=113; 78%)

    -- Treatment: 3 escalating doses (10,000 Units, 12,500 Units, 15,000

       Units)

    -- Measurement intervals: baseline, 2 weeks, every 4 weeks

    -- Effectiveness measurements:

       -- Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total

          Score (Torticollis Severity, Disability, Pain)

       --
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Sclerosis Drugs Market 2014-2018" report to their offering. ... medical condition that results in demyelination, axonal transection, and ... abnormal response by the immune system, which targets neurons ... potentially debilitating disease in which the damage of the ...
(Date:8/29/2014)... 29, 2014 Pixcelldata, the innovative ... has announced a major new deal with Dutch based ... pathology expert, Dr. Marius Nap . ... European Congress of Pathology which is taking placing between ... London where Pixcelldata will demonstrate ...
(Date:8/28/2014)... 28, 2014  Rigrodsky & Long, P.A.: , ... (NYSE: LCI )? , Did you purchase your ... July 16, 2014, inclusive? , Did you lose money ... you want to discuss your rights? ... Attorney, Timothy J. MacFall , announces that a complaint has ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or ... marketing and sale of medical devices and homecare medical ... Weibing Yang as and Dr. Genhui Chen directors of ... fills the vacancy resulting from the resignation of Ms. ...
...  Researchers have published the largest single patient population ... patients with retrievable inferior vena cava (IVC) filters—devices ... the lungs. This study, which is important for ... existing guidelines developed by the Society of Interventional ...
Cached Medicine Technology:Dehaier Medical Announces Changes to Board of Directors 2Dehaier Medical Announces Changes to Board of Directors 3IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research 2IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research 3IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research 4
(Date:8/29/2014)... New ESC registries are being launched on cardiac ... comes as the long-term phase of the cardiomyopathy ... failure patients conducted in collaboration with the Organisation ... outcomes evaluation. , The registries are all part ... Professor Roberto Ferrari, Chairperson of EORP, said: "The ...
(Date:8/29/2014)... As a chiropractic physician and medical ... there’s a direct connection between the condition of the ... "Since conventional shoe inserts and orthotics weren’t satisfying my ... own," he said. , Customizable to a user’s needs, ... the foot in order to help prevent pain in ...
(Date:8/29/2014)... August 29, 2014 Glendale Botox ... promotion on Botox throughout the month of September. This special ... of two syringes of Juvederm. Patients can take advantage of ... skin. The Glendale Botox experts will work with patients to ... , What is Botox? , Botox is a ...
(Date:8/29/2014)... 2014 (HealthDay News) -- The main strain of ... East and North Africa originated in sub-Saharan Africa, ... community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections, ... recently been hospitalized. These infections typically affect the ... or through touching contaminated objects such as clothing ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- The way ... the baby,s language development, a new study suggests. ... mothers and their infants during free play. The sessions ... The infants were 8 months old at the start ... to a baby,s babbling, infants began to form complex ...
Breaking Medicine News(10 mins):Health News:New ESC registries launched on cardiac oncology and ACS 2Health News:New ESC registries launched on cardiac oncology and ACS 3Health News:New ESC registries launched on cardiac oncology and ACS 4Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News: European MRSA Originated in Sub-Saharan Africa, Study Finds 2Health News:Encouraging Your Baby's Babbling May Speed Language Development 2
... published in the November issue of the Springer journal ... absorptiometry has been cut to levels substantially below the ... physicians and clinics around the country are likely to ... access to the test and jeopardizing those at risk ...
... Employees,International Union (SEIU), the nation,s largest labor union for ... the diagnosis of,and prescription for mending our broken health ... On the heels of a historic election where voters ... health care costs as their number one,economic concern -- ...
... Regarding Protecting,Children from the Flu, ARLINGTON, Va., Nov. 12 , ... of Child Care Professionals (NACCP), Families ... Coalition (CIIC) are launching the second annual nationwide flu ... in Child Care Settings: Building Blocks ...
... Team by 30%, MENLO PARK, Calif., Nov. ... a leading venture capital firm celebrating,40 years of ... its,fundraising goal and closed its ninth fund at ... total capital under management to $2.6,billion. Morgenthaler Venture ...
... launched a totally new advanced skincare range that is designed ... just for ... millions of,concerned mums who have 12-24 year old boys suffering with spots ... totally new advanced skincare range that is designed,just for boys, helping to ...
... whites, 19% for blacks, 21% for Hispanics and 27% for ... -- Minority children waiting for a heart transplant have a ... eight years of data from the United Network of Organ ... 3,299 children waiting for a heart transplant. Of those, 58 ...
Cached Medicine News:Health News:Osteoporosis care at risk in the United States 2Health News:SEIU Statement in Support of New Blueprint to Solve Health Care Crisis by Senator Max Baucus 2Health News:Audio: NACCP, Families Fighting Flu, and the Childhood Influenza Immunization Coalition Team Up to Educate Families About Annual Childhood Flu Vaccination 2Health News:Audio: NACCP, Families Fighting Flu, and the Childhood Influenza Immunization Coalition Team Up to Educate Families About Annual Childhood Flu Vaccination 3Health News:Audio: NACCP, Families Fighting Flu, and the Childhood Influenza Immunization Coalition Team Up to Educate Families About Annual Childhood Flu Vaccination 4Health News:Morgenthaler Closes Ninth Fund at $400 Million 2Health News:Morgenthaler Closes Ninth Fund at $400 Million 3Health News:Morgenthaler Closes Ninth Fund at $400 Million 4Health News:OXY Launches Young Male Skincare Range - a UK First 2Health News:Death Rates Higher for Minority Children Awaiting Heart Transplant 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: